EP 1879887 A2 20080123 - NPY ANTAGONISTS, PREPARATION AND USE
Title (en)
NPY ANTAGONISTS, PREPARATION AND USE
Title (de)
NPY ANTAGONISTEN, HERSTELLUNG UND ANWENDUNG
Title (fr)
ANTAGONISTES NPY, PREPARATION ET UTILISATIONS
Publication
Application
Priority
- FR 2006000829 W 20060414
- FR 0503795 A 20050415
Abstract (en)
[origin: WO2006108965A2] The invention relates to novel compounds, to the preparation and use thereof, in particular therapeutic. Said invention particularly relates to derived compounds comprising at least two aromatic cycles, to the preparation and use thereof, mainly for human and animal health care. Said compounds exhibit an affinity to biological receptors Y and NPY of a neuropeptide Y which are present in the central and peripheral nervous systems. The inventive compounds are preferably embodied in the form NPY antagonists, and more particularly in the form of NPY Y1 subtype antagonists and, whereby are usable in therapeutic or prophylactic treatment all NPY involving disorders. Pharmaceutical compositions comprising said compounds, the preparation and the use thereof and treating methods using said compounds are also disclosed.
IPC 8 full level
C07D 417/12 (2006.01); A61K 31/452 (2006.01); A61P 3/00 (2006.01); C07D 211/42 (2006.01); C07D 211/46 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 453/06 (2006.01); C07D 471/08 (2006.01)
CPC (source: EP KR US)
A61K 31/452 (2013.01 - KR); A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 3/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/06 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/24 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/08 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/32 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 211/42 (2013.01 - EP KR US); C07D 211/46 (2013.01 - EP US); C07D 295/08 (2013.01 - KR); C07D 295/088 (2013.01 - EP US); C07D 401/12 (2013.01 - EP KR US); C07D 413/12 (2013.01 - EP US); C07D 417/12 (2013.01 - EP US); C07D 417/14 (2013.01 - EP US); C07D 453/06 (2013.01 - EP US); C07D 471/08 (2013.01 - EP US)
Citation (search report)
See references of WO 2006108965A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK YU
DOCDB simple family (publication)
WO 2006108965 A2 20061019; WO 2006108965 A3 20070329; AP 2007004218 A0 20071031; AU 2006234413 A1 20061019; CA 2604773 A1 20061019; CN 101198604 A 20080611; CR 9514 A 20080826; EA 200800157 A1 20080428; EC SP077894 A 20080326; EP 1879887 A2 20080123; FR 2884516 A1 20061020; FR 2884516 B1 20070622; IL 186601 A0 20080120; JP 2008538749 A 20081106; KR 20080009112 A 20080124; MA 29444 B1 20080502; MX 2007012847 A 20080325; NI 200700260 A 20090303; NO 20075322 L 20080111; TN SN07376 A1 20090317; US 2009233910 A1 20090917
DOCDB simple family (application)
FR 2006000829 W 20060414; AP 2007004218 A 20060414; AU 2006234413 A 20060414; CA 2604773 A 20060414; CN 200680021275 A 20060414; CR 9514 A 20071113; EA 200800157 A 20060414; EC SP077894 A 20071113; EP 06743700 A 20060414; FR 0503795 A 20050415; IL 18660107 A 20071011; JP 2008505929 A 20060414; KR 20077026216 A 20071112; MA 30359 A 20071107; MX 2007012847 A 20060414; NI 200700260 A 20060414; NO 20075322 A 20071017; TN SN07376 A 20071005; US 91847006 A 20060414